Bookmarks
Multi-Arm Trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)
Safe People
Organisation name
Imperial College London
Organisation sector
Academic Institute
Applicant name(s)
Nichola Cooper
Funders/ Sponsors
Erik Mayer
DEA accredited researcher?
Unknown
Sub-licence arrangements (if any)?
No
Safe Projects
Project ID
NIBDAPC_2022_0015
Lay summary
This research is being undertaken on a lung disease called COVID-19. This condition is caused by a type of virus called SARS-CoV-2. In people who have been admitted to hospital with COVID-19 pneumonia (lung infection), many will develop severe disease, which can result in needing ventilation and some people may not survive. There is currently no cure or effective treatment for COVID-19, although steroids, including dexamethasone has shown some improvement, we still need to find new treatments to stop people getting more sick. There is a lot of evidence now that some of what makes people sick is the body’s response to the virus. Steroids work a little bit on this, but not enough. This study aims to find out whether some other treatments, which have been used for other diseases could stop the development of severe disease in patients who have been hospitalised with COVID-19. These treatments are anti-inflammatory treatments and they show promise, however, nobody knows if any of them will turn out to be more effective in helping patients recover than the usual standard of care. This data collected will be used as part of a long covid substudy to assess the longer term clinical outcomes from patients who were enrolled onto the trial. We will assess long term outcomes including death, patients being admitted to hospital again and blood clots in order to determine whether the study drugs have any impact on these outcomes and/or long covid.
Public benefit statement
COVID-19 is a signficiant public health problem, and has resulted in significant morbidity and mortality worldwide. The MATIS trial aimed to trial new medications in the treatment of COVID-19. This follow-up substudy aims to assess the impact of these medications (Ruxolitinib and fostamatinib) on the longer term patient outcomes, as well as the development of long covid. This may change current COVID guidelines and inform future prioritised research and therefore will be potentially of significant benefit for patients. Many MATIS trial participants on follow up phone calls and visits have been concerned by ongoing COVID symptoms and Long covid has been highly publicised in the media, and therefore we believe this to be an important concern and patient-focused.
Request category type
Public Health Research
Other approval committees
Latest approval date
29/07/2022
Safe Data
Dataset(s) name
ICHT MATIS Dataset
Data sensitivity level
De-Personalised
Common Law Duty of Confidentiality
Not applicable
National data opt-out applied?
Not applicable
Request frequency
One-off
Safe Setting
Access type
TRE